Bifogade filer
Kurs
-17,78%
Kurs
-17,78%
Open
198,90
High
202,00
Low
167,50
Close
174,80
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
151 MSEK
Likviditet
151 MSEK
Rel. mcap
0,72%
Antal aktier
860 725
Likviditet under dagen för detta pressmeddelande
Kalender
Est. tid* | ||
2026-01-29 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-17 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-04-30 | - | X-dag ordinarie utdelning VITR 1.10 SEK |
2025-04-29 | - | Årsstämma |
2025-04-24 | - | Kvartalsrapport 2025-Q1 |
2025-01-30 | - | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-17 | - | Kvartalsrapport 2024-Q2 |
2024-04-26 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
2024-04-25 | - | Årsstämma |
2024-04-18 | - | Kvartalsrapport 2024-Q1 |
2024-02-02 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-04-28 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
2023-04-27 | - | Årsstämma |
2023-04-21 | - | Kvartalsrapport 2023-Q1 |
2023-02-02 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-04-28 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
2022-04-27 | - | Årsstämma |
2022-04-22 | - | Kvartalsrapport 2022-Q1 |
2022-02-16 | - | Bokslutskommuniké 2021 |
2021-10-29 | - | Kvartalsrapport 2021-Q3 |
2021-10-20 | - | Extra Bolagsstämma 2021 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-04-29 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
2021-04-28 | - | Årsstämma |
2021-04-22 | - | Kvartalsrapport 2021-Q1 |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-07-13 | - | Kvartalsrapport 2020-Q2 |
2020-06-16 | - | X-dag ordinarie utdelning VITR 0.00 SEK |
2020-06-15 | - | Årsstämma |
2020-04-23 | - | Kvartalsrapport 2020-Q1 |
2020-02-06 | - | Bokslutskommuniké 2019 |
2019-11-06 | - | Kvartalsrapport 2019-Q3 |
2019-07-12 | - | Kvartalsrapport 2019-Q2 |
2019-05-03 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
2019-05-02 | - | Årsstämma |
2019-04-23 | - | Kvartalsrapport 2019-Q1 |
2019-02-08 | - | Bokslutskommuniké 2018 |
2018-11-06 | - | Kvartalsrapport 2018-Q3 |
2018-07-13 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | Split VITR 1:5 |
2018-04-27 | - | X-dag ordinarie utdelning VITR 3.70 SEK |
2018-04-26 | - | Årsstämma |
2018-04-24 | - | Kvartalsrapport 2018-Q1 |
2018-02-08 | - | Bokslutskommuniké 2017 |
2017-11-02 | - | Kvartalsrapport 2017-Q3 |
2017-07-14 | - | Kvartalsrapport 2017-Q2 |
2017-04-28 | - | X-dag ordinarie utdelning VITR 2.60 SEK |
2017-04-27 | - | Årsstämma |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-02-09 | - | Bokslutskommuniké 2016 |
2016-11-03 | - | Kvartalsrapport 2016-Q3 |
2016-09-20 | - | Kapitalmarknadsdag 2016 |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
2016-04-29 | - | X-dag ordinarie utdelning VITR 2.40 SEK |
2016-04-28 | - | Årsstämma |
2016-04-26 | - | Kvartalsrapport 2016-Q1 |
2016-02-05 | - | Bokslutskommuniké 2015 |
2015-11-05 | - | Kvartalsrapport 2015-Q3 |
2015-07-14 | - | Kvartalsrapport 2015-Q2 |
2015-05-06 | - | X-dag ordinarie utdelning VITR 1.50 SEK |
2015-05-05 | - | Årsstämma |
2015-04-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-06 | - | Bokslutskommuniké 2014 |
2014-11-06 | - | Analytiker möte 2014 |
2014-11-06 | - | Kapitalmarknadsdag 2014 |
2014-11-06 | - | Kvartalsrapport 2014-Q3 |
2014-07-11 | - | Kvartalsrapport 2014-Q2 |
2014-05-06 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
2014-05-05 | - | Årsstämma |
2014-04-23 | - | Kvartalsrapport 2014-Q1 |
2014-02-06 | - | Bokslutskommuniké 2013 |
2013-11-11 | - | Kapitalmarknadsdag 2013 |
2013-11-07 | - | Analytiker möte 2013 |
2013-11-07 | - | Kvartalsrapport 2013-Q3 |
2013-07-12 | - | Kvartalsrapport 2013-Q2 |
2013-04-30 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
2013-04-29 | - | Årsstämma |
2013-04-19 | - | Kvartalsrapport 2013-Q1 |
2013-03-13 | - | 15-7 2013 |
2013-02-07 | - | Bokslutskommuniké 2012 |
2012-11-01 | - | Analytiker möte 2012 |
2012-11-01 | - | Kvartalsrapport 2012-Q3 |
2012-09-24 | - | Extra Bolagsstämma 2012 |
2012-07-13 | - | Kvartalsrapport 2012-Q2 |
2012-04-20 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
2012-04-19 | - | Årsstämma |
2012-04-19 | - | Kvartalsrapport 2012-Q1 |
2012-02-07 | - | Bokslutskommuniké 2011 |
2011-10-27 | - | Kvartalsrapport 2011-Q3 |
2011-07-14 | - | Kvartalsrapport 2011-Q2 |
2011-04-28 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
2011-04-27 | - | Årsstämma |
2011-04-27 | - | Kvartalsrapport 2011-Q1 |
2011-02-09 | - | Bokslutskommuniké 2010 |
2010-11-02 | - | Kvartalsrapport 2010-Q3 |
2010-07-15 | - | Kvartalsrapport 2010-Q2 |
2010-04-27 | - | X-dag ordinarie utdelning VITR 0.50 SEK |
2010-04-27 | - | Kvartalsrapport 2010-Q1 |
2010-04-26 | - | Årsstämma |
2010-02-05 | - | Bokslutskommuniké 2009 |
2009-11-03 | - | Kvartalsrapport 2009-Q3 |
2009-07-15 | - | Kvartalsrapport 2009-Q2 |
2009-04-28 | - | X-dag ordinarie utdelning VITR 0.40 SEK |
2009-04-27 | - | Årsstämma |
2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
2023-07-14 08:00:00
Second quarter
- Sales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.
- Sales, in local currencies and excluding discontinued business, increased by 19% in APAC, and 3% in EMEA, while sales in Americas decreased by 6%.
- Sales, in local currencies and excluding discontinued business, increased by 17% in Consumables, Technologies decreased by 7% and Genetic Services decreased by 4%.
- Gross margin was 55.8% (56.8), negatively impacted by non-recurring costs of SEK 6 million, giving a run-rate gross margin of 56.5%.
- Operating income before depreciation and amortisation (EBITDA) was SEK 293 (273) million. Adjusted for non-recurring costs, EBITDA was SEK 299 million, giving an EBITDA margin of 33.0% (32.9).
- Operating cash flow increased to SEK 211 million (180).
- Net income was SEK 106 (130) million, including non-recurring costs, resulting in earnings per share of SEK 0.78 (0.96).
First half year
- Sales of SEK 1,759 (1,581) million, an increase of 11%, or 13% excluding discontinued business. In local currencies, growth was 5% and excluding discontinued business 6%.
- Sales, in local currencies and excluding discontinued business, increased by 21% in APAC, 2% in EMEA and 0% in Americas.
- Sales, in local currencies and excluding discontinued business, increased by 14% in Consumables, Technologies growth was 0% and Genetic Services increased by 1%.
- Gross margin increased to 56.3% (56.2).
- Operating income before depreciation and amortisation (EBITDA) was SEK 554 (501) million. Adjusted for non-recurring costs of SEK 26 million, EBITDA was SEK 580 (501) million, giving an EBITDA margin of 33.0% (31.7).
- Operating cash flow increased to SEK 372 million (270).
- Net income was SEK 205 (213) million, including non-recurring costs, resulting in earnings per share of SEK 1.52 (1.56).
Gothenburg, July 14, 2023
VITROLIFE AB (publ)
Jón Sigurdsson, interim CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 14-07-2023 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.